Scotiabank initiates coverage of Mirati Therapeutics at 'sector underperform' with a price target of $20.00

  • Investing.com
Scotiabank initiates coverage of Mirati Therapeutics at 'sector underperform' with a price target of $20.00

An analyst from Scotiabank initiated coverage of Mirati Therapeutics (NASDAQ: MRTX ) at 'sector underperform' with a price target of $20.00.

Prior to this rating, Mirati Therapeutics had 9 buy ratings, 7 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Mirati Therapeutics, click here. For more news on Mirati Therapeutics, click here.

Mirati Therapeutics's stock price closed at $29.98. They are down -18.97% in the last month and down -54.98% in the last 12 months.

According to Investing Pro, Mirati Therapeutics's fair value is $34.85, an upside of 16.25%. Mirati Therapeutics's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out Mirati Therapeutics's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles